LitAlert ~~ GeneLit.com

    • Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.
    • Liu M, Xie F, Liu M, Zhang Y, Wang S.
    • Breast Cancer Res Treat. 2021 Feb 9. doi: 10.1007/s10549-021-06104-y. Epub ahead of print.
    • Review
    • Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms.
    • Tukachinsky H, Madison RW, Chung JH, Gjoerup O, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons AD, Loehr A, Venstrom JM, Oxnard GR.
    • Clin Cancer Res. 2021 Feb 9. doi: 10.1158/1078-0432.CCR-20-4805. Epub ahead of print.
    • Characteristics of BRCA1/2 pathogenic germline mutations in chinese NSCLC patients and a comparison with HBOC.
    • Xu Z, Wang Y, Wang L, Cui F, Zhang L, Xiong J, Peng H.
    • Hered Cancer Clin Pract. 2021 Feb 9;19:16. doi: 10.1186/s13053-021-00174-1.
    • Downstream Revenue Generated by a Cancer Genetic Counselor.
    • Mauer CB, Reys BD, Hall RE, Campbell CL, Pirzadeh-Miller SM.
    • JCO Oncol Pract. 2021 Feb 8:OP2000464. doi: 10.1200/OP.20.00464. Epub ahead of print.
    • DNA damage response inhibitors: An avenue for TNBC treatment.
    • Jin J, Tao Z, Cao J, Li T, Hu X.
    • Biochim Biophys Acta Rev Cancer. 2021 Feb 5:188521. doi: 10.1016/j.bbcan.2021.188521. Epub ahead of print.
    • Review
    • Management of a Prostate Cancer Patient with inherited germline BRCA1 and BRCA2 mutations, a Case Report.
    • Hemal S, DeWitt-Foy M, Klein EA.
    • Urology. 2021 Feb 5:S0090-4295(21)00120-5. doi: 10.1016/j.urology.2020.11.076. Epub ahead of print.
    • Case report